Skip to main content
GYRE
NASDAQ Life Sciences

Officer Files Intent to Sell $2.12M in Shares Amidst Post-Acquisition Leadership Changes

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$7.47
Mkt Cap
$724.545M
52W Low
$6.57
52W High
$11.78
52W Position info
14% above low
Off High info
37% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

GYRE is trading near its 52-week low of $6.57 (14% above the low).

Summary

Officer Ye Weiguo has filed a Form 144, indicating an intent to sell 300,000 common shares of GYRE THERAPEUTICS, INC., valued at approximately $2.12 million.


Key Events · Ownership and Investor Activity · GYRE

  • Officer Files Intent to Sell Shares

    Officer Ye Weiguo has filed a Form 144, indicating an intent to sell 300,000 common shares with an approximate market value of $2,121,000.00.

  • Shares Acquired via Option Exercise

    The shares intended for sale were acquired through a stock option exercise on March 24, 2025.

  • Context of Recent Corporate Activity

    This intent to sell follows the company's recent completion of the $300 million all-stock acquisition of Cullgen Inc. and the appointment of new executive leadership on May 4, 2026.


Analysis · GYRE · Life Sciences

This filing indicates an officer's intent to sell a significant block of shares, which could be perceived by the market as a move for personal liquidity or diversification. Coming shortly after the company's major acquisition of Cullgen and related leadership changes, this transaction may draw additional scrutiny regarding insider sentiment during a period of significant corporate transformation and integration.

How filings like this one have moved

In the 30 days to Sep 15, 2026, 29.9% of the 1678 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.25%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, GYRE was trading at $7.47 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $724.5M. The 52-week trading range was $6.57 to $11.78. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

GYRE - Latest Insights

GYRE
Aug 07, 2026, 5:00 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $6.67
Real-time Price: $6.69 info
Change: +$0.020 (+0.30%) info
Market Cap: $709.366M info
GYRE
Aug 07, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $6.40
Real-time Price: $6.69 info
Change: +$0.290 (+5%) info
Market Cap: $709.366M info
GYRE
Jul 15, 2026, 5:09 PM EDT
Filing Type: 8-K/A
Importance Score:
7
Price at Filing: $6.56
Real-time Price: $6.69 info
Change: +$0.130 (+2%) info
Market Cap: $709.366M info
GYRE
Jun 22, 2026, 7:16 PM EDT
Filing Type: S-3
Importance Score:
8
Price at Filing: $6.34
Real-time Price: $6.69 info
Change: +$0.350 (+6%) info
Market Cap: $709.366M info
GYRE
Jun 16, 2026, 6:30 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $5.80
Real-time Price: $6.69 info
Change: +$0.890 (+15%) info
Market Cap: $709.366M info